Market capitalization | $432.51m |
Enterprise Value | $334.02m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.82 |
P/S ratio (TTM) P/S ratio | 4.94 |
P/B ratio (TTM) P/B ratio | 2.58 |
Revenue growth (TTM) Revenue growth | 24.05% |
Revenue (TTM) Revenue | $87.49m |
As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.
6 Analysts have issued a Personalis Inc forecast:
6 Analysts have issued a Personalis Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 87 87 |
24%
24%
|
|
Gross Profit | 27 27 |
79%
79%
|
|
EBITDA | -59 -59 |
38%
38%
|
EBIT (Operating Income) EBIT | -70 -70 |
35%
35%
|
Net Profit | -91 -91 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | Christopher Hall |
Employees | 225 |
Founded | 2011 |
Website | www.personalis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.